On this page

PROHIBIT®

Levamisole Hydrochloride

Veterinary ANADA Approved 98 adverse event reports

Overview

Source: Animal Drugs @ FDA
Proprietary name
PROHIBIT®
Active ingredient
Levamisole Hydrochloride
Application type
ANADA
Sponsor
Huvepharma EOOD
Applications on record
1
First published
May 20, 2024

Adverse event reports

Source: openFDA VeDDRA
98
Reports mentioning this ingredient
February 20, 1987 – July 11, 2025
4
Classified serious
per reporter assessment
2
Lack of expected efficacy
resistance signal
4
Human operator exposure
needle-stick or splash
Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “LEVAMISOLE HYDROCHLORIDE”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term) Reports Relative frequency
Death 52
Hypersalivation 24
Depression 13
Ataxia 13
Trembling 12
Recumbency 8
Dyspnoea 7
Vomiting 7
Weakness 6
Abortion 5
Convulsion 5
Unclassifiable adverse event 5
Cough 4
Anaphylaxis 4
Twitching 4
Accidental exposure 4
Fever 3
Diarrhoea 3
Hyperactivity 3
PR-LUNG(S), LESION(S) 3

Species affected

Source: openFDA VeDDRA
Sheep 34 Cattle 20 Dog 16 Goat 9 Pig 7 Human 6 Horse 3 Cat 1

Regulatory context

Abbreviated New Animal Drug Application (ANADA). A generic animal drug demonstrating bioequivalence, pharmaceutical equivalence and identical manufacturing criteria to the pioneer application. Veterinary generics have no formal therapeutic-equivalence coding system; they match the pioneer NADA specification instead.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA FDA CVM Applications, sponsor, status, withdrawal
Animal & Veterinary Events FDA CVM VeDDRA adverse event aggregates by active ingredient